PRESS RELEASE Stockholm, Sweden, May 2, 2006 Six Elekta Synergy® systems, the leading system for intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT), have been purchased by Providence Health System. The health system, which operates 18 acute care facilities in four states, signed an exclusive, five-year provider contract with Elekta in September, 2005.
The six Elekta Synergy systems will be installed at Providence Portland Medical Center (Oregon), Valley Radiation Oncology Center (California) and the new Roy and Patricia Disney Cancer Center (California). Providence Health System chose Elekta Synergy for image guided and stereotactic radiation therapy (IGRT and SRT) based on Elekta’s unique technology for integrated 3D volumetric imaging at the time of treatment. The total value of these orders is in excess of USD 11 M and was booked by Elekta in April.
“We are always seeking ways to improve the quality of care that we provide patients. The highly advanced technology of Elekta Synergy allows us to more accurately target cancer while sparing healthy tissue, thereby ensuring a better quality of life for our patients,” said Steven Seung, M.D., Ph.D., Director of The Gamma Knife® Center of Oregon and Radiation Oncologist at The Oregon Clinic. “In addition, as a not-for-profit organization, we seek solutions that are as cost-efficient as they are effective, and Elekta Synergy amply satisfied that criteria.”
Only Elekta offers true 3D X-ray Volume Imaging at the time of treatment, enabling visualization of soft tissue structures as treatment is being provided. Elekta’s unique experience in image guidance and stereotactic applications in radiation treatment reaches back more than 30 years. On the basis of this experience and recent innovations that set new standards for radiotherapy precision, Elekta leads the development of advanced methods for ultra-precise radiation treatments.
“We are proud to have been chosen as a long-term partner in Providence’s ongoing expansion of oncology care capacity and clinical improvement program,” said Anthony De Carolis, President & CEO of Elekta, Inc. and head of Elekta’s operations in North America. “This collaboration is another proof of Elekta’s clinical and technological leadership in advanced methods in radiation oncology, currently resulting in a rapid growth and a strengthening of Elekta’s position in the highly competitive U.S. market.”
Elekta’s radiation oncology and stereotactic radiosurgery solutions are readily available to over 80 percent of acute care hospitals that provides radiation therapy, thanks to contracts with several of the nation’s largest healthcare group purchasing organizations (GPOs).